Introduction and Objective: Short-term use of a single stand-alone 14-day continuous glucose monitoring (CGM) improves glycemic awareness and self-management in non-insulin-treated (NIT) patients with type 2 diabetes (PwT2D). This study examined whether supplementing short-term CGM use of 9-14 days with access to a digital learning platform or a blended in-person course and webinar enhances self-reported short-term benefits of CGM use.Methods: In total, 1,081 CGM-naïve NIT PwT2D received a CGM and were allocated to one of three groups: no instructions (n=401), access to a digital learning platform (n=541), or participation in a four-hour professional, hands-on, blended course and webinar (n=139). Four learning outcomes and seven lifestyle changes were assessed at a two-week follow-up questionnaire.Results: A total of 688 participants wore the CGM for 9-14 days and completed the follow-up questionnaire. Across the three groups, participants reported a mean of 2.8 learning outcomes (SD 1.2) and 1.8 lifestyle changes (SD 1.4). Without instructions, PwT2D diagnosed <5 years ago reported 0.44 more learning outcomes and 0.51 more lifestyle changes compared with PwT2D diagnosed ≥5 years ago. Neither digital platform access nor course participation conferred enhanced benefits among PwT2D diagnosed <5 years ago. In contrast, among PwT2D diagnosed ≥5 years ago, course participation increased learning outcomes by 0.64 and lifestyle changes by 0.74 compared to no instructions, corresponding to small-to-moderate effect sizes (0.18 and 0.19 SD). Digital platform access, however, had no enhanced benefit.Conclusion: For recently diagnosed NIT PwT2D, a single 9-14-day stand-alone CGM intervention improves glycemic awareness and self-management, without enhanced short-term benefits of supplemental education. In contrast, for PwT2D diagnosed ≥5 years ago, participation in a professional course correlated with modest, but consistent improvements in learning outcomes and lifestyle changes, enhancing the short-term benefits of CGM use.
N. Cayuelas Mateu: Other – charitable donation of 1100 sensors; Current; Abbott Diabetes. A.K. Wegener: Other – Charitable donation of 1100 sensors; Current; Abbott Diabetes. E. Munch Nielsen: Other – Charitable donation of 1100 sensors; Current; Abbott Diabetes. W. Ravn: Other – charitable donation of 1100 sensors; Current; Abbott Diabetes. T.T. Thybo: Other – donation of 1100 freestyle libre 2; Current; Abbott Diabetes. Other – donation of 3000 HbA1c test kassettes; Current; Abbott Diagnostics. Research Support; Current; Bayer AG, Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Sanofi.
Source link
Leave a Reply